- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
York Pharma raises £28 million to fund acquisitions
Milton Keynes, England - York Pharma has raised £28 million to fund a multi-million pound acquisition of Flammazine and Flammacerium from Solvay, according to BusinessWeekly.co.uk.
Milton Keynes, England
- York Pharma has raised £28 million to fund a multi-million pound acquisition of Flammazine and Flammacerium from Solvay, according to BusinessWeekly.co.uk.
York Pharma has agreed to to terms for a £24.2 million for debt financing and another £3.9 million raised as it takes on global commercial rights and current sales of Flammazine and Flammacerium.
Flammazine and Flammacerium are dermatologic brands for the prevention and treatment of infections in burn wounds and topical wound infections.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
